Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature.

Antiangiogenic drugs are currently standard of care in adults with renal cell carcinoma (RCC), including translocation RCC. Although antitumor activity and toxicity profile are well known in adults, few data have been reported in children. Here we present the case of a patient diagnosed at 2 years old with a metastatic translocation RCC, consecutively treated with 5 tyrosine kinase inhibitors during 6 years. The antitumor activity and toxic effects are described, and a brief review of the literature is presented.

[1]  B. Widemann,et al.  Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group , 2015, Pediatric blood & cancer.

[2]  S. Vajapeyam,et al.  A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors , 2015, Child's Nervous System.

[3]  P. Adamson,et al.  Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti‐angiogenic therapy: A report from the children's oncology group phase I consortium , 2015, Pediatric blood & cancer.

[4]  Anita Gupta,et al.  Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab , 2014, Pediatric blood & cancer.

[5]  Erika J. Thompson,et al.  Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes , 2014, Clinical Cancer Research.

[6]  S. Baruchel,et al.  Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. Tamboli,et al.  Genomic Heterogeneity of Translocation Renal Cell Carcinoma , 2013, Clinical Cancer Research.

[8]  S. Steinberg,et al.  Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma , 2013, Clinical Cancer Research.

[9]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[10]  P. Choyke,et al.  Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas , 2013, Pediatric blood & cancer.

[11]  I. Pollack,et al.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Sebire,et al.  Persistent Complete Response After Single-agent Sunitinib Treatment in a Case of TFE Translocation Positive Relapsed Metastatic Pediatric Renal Cell Carcinoma , 2013, Journal of pediatric hematology/oncology.

[13]  M. Souweidane,et al.  Extraneural ependymoma: Distant bone, lung, liver, and lymph node metastases following bevacizumab , 2013, Pediatric blood & cancer.

[14]  J. Feusner,et al.  Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: Stable radiographic disease with decreased AFP , 2012, Pediatric blood & cancer.

[15]  S. Baruchel,et al.  A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report , 2012, Clinical Cancer Research.

[16]  J. Schellens,et al.  Concise drug review: pazopanib and axitinib. , 2012, The oncologist.

[17]  S. Baruchel,et al.  A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report , 2012, Clinical Cancer Research.

[18]  H. Brisse,et al.  Alveolar soft part sarcoma in childhood: Is Sunitinib‐Sutent® treatment an effective approach? , 2012, Pediatric blood & cancer.

[19]  J. Mora,et al.  Antiangiogenic treatment as a pre‐operative management of alveolar soft‐part sarcoma , 2011, Pediatric blood & cancer.

[20]  S. Baruchel,et al.  Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study , 2011, Clinical Cancer Research.

[21]  P. Adamson,et al.  A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Amar Gajjar,et al.  Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Karl J. Dykema,et al.  Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study , 2010, Molecular Cancer Therapeutics.

[24]  P. Camparo,et al.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. MacDonald,et al.  Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors , 2009, Pediatric blood & cancer.

[26]  Helen X. Chen,et al.  Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Roskoski,et al.  Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. , 2007, Biochemical and biophysical research communications.

[28]  M. Ladanyi,et al.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. , 2007, Cancer research.

[29]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[30]  A. Renshaw.  Pediatric Renal Cell Carcinomas: Where Do They Fit in the New Histologic Classification of Renal Cell Carcinoma? , 2000, Advances in anatomic pathology.

[31]  I. Pollack,et al.  Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study , 2014, Journal of Neuro-Oncology.

[32]  M. Schmidinger.  Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[33]  D. Ben-Bashat,et al.  LONG-TERM EFFICACY AND TOXICITY OF BEVACIZUMAB-BASED THERAPY IN CHILDREN WITH RECURRENT LOW-GRADE GLIOMAS , 2012 .

[34]  P. Keegan,et al.  FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. , 2010, The oncologist.

[35]  W. Stadler,et al.  Novel kinase inhibitors in renal cell carcinoma: Progressive development of static agents , 2005, Current oncology reports.

[36]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.